Allarity Financials

ALLR

Source SEC Filings (10-K/10-Q) Updated Mar 30, 2026 Currency USD FYE March

This page shows Allarity (ALLR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

1.32x

For every $1 of reported earnings, Allarity generates $1.32 in operating cash flow (-$14.8M OCF vs -$11.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-63.0x

Allarity earns $-63.0 in operating income for every $1 of interest expense (-$12.6M vs $200K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$320K

Allarity generated $320K in revenue in fiscal year 2025.

EBITDA

N/A

Net Income

-$11.2M

YoY+54.2%

Allarity reported -$11.2M in net income in fiscal year 2025. This represents an increase of 54.2% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$14.8M

YoY+16.0%

Allarity generated -$14.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 16.0% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

16M

YoY+116.6%

Allarity had 16M shares outstanding in fiscal year 2025. This represents an increase of 116.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-3939.1%

Allarity's operating margin was -3939.1% in fiscal year 2025, reflecting core business profitability.

Net Margin

-3509.7%

Allarity's net profit margin was -3509.7% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

N/A

Capital Allocation

R&D Spending

$6.6M

YoY+8.3%

5Y CAGR+9.4%

Allarity invested $6.6M in research and development in fiscal year 2025. This represents an increase of 8.3% from the prior year.

Share Buybacks

$3.2M

Allarity spent $3.2M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$8K

YoY-97.3%

5Y CAGR+21.7%

Allarity invested $8K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 97.3% from the prior year.

ALLR Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$320K	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	-$2.3M	N/A	N/A
R&D Expenses	$6.6M+8.3%	$6.1M-14.2%	$7.1M+2.5%	$6.9M-51.2%	$14.2M+236.6%	$4.2M
SG&A Expenses	$6.3M-44.7%	$11.4M+14.1%	$10.0M+0.6%	$10.0M-19.4%	$12.4M+201.4%	$4.1M
Operating Income	-$12.6M+53.7%	-$27.2M-59.0%	-$17.1M+50.3%	-$34.5M-29.8%	-$26.6M-219.2%	-$8.3M
Interest Expense	$200K-69.4%	$653K+31.1%	$498K+123.3%	$223K+125.3%	$99K+6.5%	$93K
Income Tax	-$381K0.0%	-$381K-559.0%	$83K+105.5%	-$1.5M-1243.6%	$133K-32.8%	$198K
Net Income	-$11.2M+54.2%	-$24.5M-106.0%	-$11.9M+25.9%	-$16.1M+39.7%	-$26.6M-302.7%	-$6.6M
EPS (Diluted)	N/A	N/A	$-10.26+99.7%	$-3093.42	$-4.19	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.2M-48.2%	$2.3M+65.4%	$1.4M	N/A	$1.0M-3.5%	$1.1M-51.2%	$2.2M	N/A
SG&A Expenses	$1.3M-27.4%	$1.8M+11.0%	$1.6M	N/A	$1.6M-31.3%	$2.3M+11.7%	$2.1M	N/A
Operating Income	-$2.5M+39.1%	-$4.1M-36.1%	-$3.0M	N/A	-$12.3M-265.3%	-$3.4M+20.5%	-$4.2M	N/A
Interest Expense	$57K+375.0%	$12K-78.9%	$57K	N/A	$50K-88.3%	$426K+317.6%	$102K	N/A
Income Tax	$0	$0	$0	N/A	-$377K	$0+100.0%	-$4K	N/A
Net Income	-$2.8M-20.9%	-$2.3M+15.1%	-$2.7M	N/A	-$11.6M-611.5%	-$1.6M+57.6%	-$3.8M	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	$-0.11	$-22.14	N/A

ALLR Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$22.6M+90.9%	$11.9M-18.4%	$14.5M-70.7%	$49.6M+48.6%	$33.4M
Current Assets	N/A	$22.3M+1033.5%	$2.0M-60.3%	$5.0M-76.8%	$21.4M+1148.0%	$1.7M
Cash & Equivalents	N/A	$19.5M+11666.9%	$166K-91.8%	$2.0M-89.6%	$19.6M+6462.1%	$298K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$10.8M-25.8%	$14.6M+15.5%	$12.7M-59.0%	$30.8M+244.1%	$9.0M
Current Liabilities	N/A	$10.8M-23.5%	$14.2M+26.2%	$11.2M-45.8%	$20.7M+274.5%	$5.5M
Long-Term Debt	N/A	N/A	$2.7M+1.6%	$2.6M	N/A	N/A
Total Equity	N/A	$11.8M+529.3%	-$2.8M-2334.5%	-$113K-100.6%	$18.2M-25.7%	$24.4M
Retained Earnings	N/A	-$119.0M-26.0%	-$94.5M-14.4%	-$82.5M-24.2%	-$66.5M-66.9%	-$39.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$20.8M-1.9%	$21.2M-28.7%	$29.7M+31.3%	$22.6M+11.1%	$20.4M-34.0%	$30.9M+158.0%	$12.0M+0.9%	$11.9M
Current Assets	$20.5M-2.0%	$20.9M-29.0%	$29.4M+31.7%	$22.3M+9.7%	$20.4M-4.4%	$21.3M+828.5%	$2.3M+16.4%	$2.0M
Cash & Equivalents	$16.9M-5.1%	$17.8M-29.4%	$25.2M+29.0%	$19.5M+5.6%	$18.5M-3.8%	$19.2M+6064.4%	$312K+88.0%	$166K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.8M-2.8%	$9.0M-18.3%	$11.1M+2.0%	$10.8M+46.2%	$7.4M-32.9%	$11.0M-40.1%	$18.4M+26.2%	$14.6M
Current Liabilities	$8.8M-2.8%	$9.0M-18.3%	$11.1M+2.0%	$10.8M+46.2%	$7.4M-30.2%	$10.6M-41.0%	$18.0M+27.1%	$14.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2.7M
Total Equity	$12.0M-1.3%	$12.2M-34.8%	$18.7M+58.1%	$11.8M-8.9%	$13.0M-34.6%	$19.8M+406.5%	-$6.5M-135.2%	-$2.8M
Retained Earnings	-$126.8M-2.3%	-$124.0M-1.9%	-$121.7M-2.3%	-$119.0M-6.7%	-$111.5M-11.6%	-$99.9M-1.7%	-$98.3M-4.1%	-$94.5M

ALLR Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$14.8M+14.6%	-$17.4M-36.1%	-$12.7M+24.2%	-$16.8M-13.0%	-$14.9M-105.3%	-$7.3M
Capital Expenditures	$8K-97.3%	$298K	$0-100.0%	$18K	N/A	$3K
Free Cash Flow	-$14.8M+16.0%	-$17.6M-38.5%	-$12.7M+24.3%	-$16.8M	N/A	-$7.3M
Investing Cash Flow	-$8K+97.3%	-$298K	$0-100.0%	$791K-21.3%	$1.0M+33600.0%	-$3K
Financing Cash Flow	$10.6M-71.1%	$36.8M+234.6%	$11.0M+938.7%	-$1.3M-103.9%	$33.8M+460.6%	$6.0M
Dividends Paid	N/A	$0	N/A	N/A	N/A	N/A
Share Buybacks	$3.2M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$3.4M+37.8%	-$5.5M-104.1%	-$2.7M+16.2%	-$3.2M+41.1%	-$5.4M+25.5%	-$7.3M-422.1%	-$1.4M+16.3%	-$1.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$2.3M+190.1%	-$2.6M-123.0%	$11.1M+163.1%	$4.2M-13.0%	$4.9M-81.5%	$26.3M+1806.4%	$1.4M+164.4%	$522K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$141K	N/A	N/A	N/A	$0	N/A	N/A	N/A

ALLR Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-3939.1%	N/A	N/A	N/A	N/A	N/A
Net Margin	-3509.7%	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-207.6%	N/A	N/A	-146.8%-119.7pp	-27.1%
Return on Assets	N/A	-108.2%-7.9pp	-100.3%+10.1pp	-110.4%-56.7pp	-53.7%-33.9pp	-19.8%
Current Ratio	N/A	2.06+1.9	0.14-0.3	0.44-0.6	1.03+0.7	0.31
Debt-to-Equity	N/A	0.92+1.9	-0.98+22.4	-23.40-25.1	1.70+1.3	0.37
FCF Margin	-4633.8%	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-23.4%-4.3pp	-19.1%-4.4pp	-14.6%	N/A	-89.4%-81.2pp	-8.2%	N/A	N/A
Return on Assets	-13.5%-2.5pp	-10.9%-1.8pp	-9.2%	N/A	-56.9%-51.6pp	-5.3%+26.8pp	-32.1%	N/A
Current Ratio	2.33+0.0	2.31-0.3	2.66+0.6	2.06-0.7	2.75+0.7	2.01+1.9	0.13-0.0	0.14
Debt-to-Equity	0.73-0.0	0.74+0.2	0.59-0.3	0.92+0.3	0.57+0.0	0.56+3.4	-2.85-1.9	-0.98
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

BOUNDLESS BIO INC BOLD

$24.2M

Kezar Life Sciences KZR

$54.5M

Tenax Therapeutics Inc TENX

$258.2M

Neuphoria Therapeutics Inc NEUP

$23.8M

Akari Therapeutics Plc AKTX

$5.1M

Frequently Asked Questions

What is Allarity's annual revenue?

Allarity (ALLR) reported $320K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Allarity profitable?

No, Allarity (ALLR) reported a net income of -$11.2M in fiscal year 2025, with a net profit margin of -3509.7%.

What is Allarity's operating margin?

Allarity (ALLR) had an operating margin of -3939.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Allarity's net profit margin?

Allarity (ALLR) had a net profit margin of -3509.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Allarity's free cash flow?

Allarity (ALLR) generated -$14.8M in free cash flow during fiscal year 2025. This represents a 16.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Allarity's operating cash flow?

Allarity (ALLR) generated -$14.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Allarity's capital expenditures?

Allarity (ALLR) invested $8K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Allarity spend on research and development?

Allarity (ALLR) invested $6.6M in research and development during fiscal year 2025.

Does Allarity buy back shares?

Yes, Allarity (ALLR) spent $3.2M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Allarity have outstanding?

Allarity (ALLR) had 16M shares outstanding as of fiscal year 2025.

Are Allarity's earnings high quality?

Allarity (ALLR) has an earnings quality ratio of 1.32x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Allarity cover its interest payments?

Allarity (ALLR) has an interest coverage ratio of -63.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.